Thus, up-regulation of PBMC cytotoxicity against tumor target hepatoblastoma HepG2 cell and erythroleukemia K562 cell line [9-11] may be contributed by either the NK (CD56+) or non-NK (cytolytic T which is CD56-) killer cells. This evidence concerns the gene NCAM1 and neoplasm.